Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2019-02-27 Annual Report
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2018
2019-02-27 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, an amendment to a previously filed Form 8-K. It specifically amends Item 2.02 regarding results of operations and financial condition, and includes a corrected press release for the fourth quarter and full year 2018 financial results and business update. The document is short (3955 characters) and primarily serves to correct and replace a press release exhibit rather than provide a full financial report. It does not contain comprehensive financial statements or detailed analysis itself, but rather an updated announcement. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for such filings that do not fit other specific report types.
2019-02-27 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 27, 2019. It announces the company's financial results for the fourth quarter and full year ended December 31, 2018. The text states that the press release with financial results is furnished as an exhibit and incorporated by reference. The document itself is short (3723 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such documents that announce financial results with a press release are classified as Earnings Release (ER).
2019-02-27 English
SC 13G/A
Major Shareholding Notification
2019-02-14 English
SC 13G/A
Major Shareholding Notification
2019-02-14 English
4
Director's Dealing
2019-01-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.